- 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS
-
The present invention relates to 2,4-diaminopyrimidines and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for the treatment of disease states,
- -
-
Paragraph 0632
(2018/10/30)
-
- Amino pyrimidine compound and preparation method and application thereof
-
The invention relates to an amino pyrimidine compound and a preparation method and application thereof. The amino pyrimidine compound has a structure as shown in a formula I. The formula is shown in the description. The compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The invention further relates to a medicine composition comprising the compound, a preparation methodand application thereof in preparation of anti-tumor medicines.
- -
-
Paragraph 0724; 0727; 0728; 0729
(2018/11/22)
-
- EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF
-
A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.
- -
-
Paragraph 0106; 0111; 0112; 0213; 0214
(2017/09/02)
-
- EGFR (Epidermal growth factor receptor) inhibitor and preparation method and use thereof
-
The present invention discloses an EGFR (Epidermal growth factor receptor) inhibitor and a preparation method and use thereof. In particular, the present invention relates to compounds of N-(5-((4-((2-(alkyl-substituted sulfonyl) pyridin-3-yl) amino) pyri
- -
-
Paragraph 0082; 0083; 0084
(2016/10/09)
-
- 1-PHENYLPYRROLE COMPOUNDS
-
The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1 -C3 alkyl group; R2 represents a hydroxy -C1 -C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1 -C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like,- R5 represents a sulfamoyl group or a C1-C3 alkylsulf onyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.
- -
-
Page/Page column 37-38
(2010/04/28)
-
- ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10
-
The invention relates to imidazo[1,5-a]pyrazine derivatives, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.
- -
-
Page/Page column 36
(2009/06/27)
-